Motlagh RS, Abufaraj M, Karakiewicz PI, et al. - A non-significant relationship was observed between the risk of SARS-CoV-2 infection and COVID-19 severity in prostate cancer (PCa) patients treated with androgen deprivation therapy (ADT). The outcomes imply that during the COVID-19 pandemic PCa patients can safely undergo ADT as a cancer therapy without worsening COVID-19 risk and trajectory.

• Researchers performed a systematic review and meta-analysis according to PRISMA guidelines selecting a total of six retrospective studies (n = 50,220 patients) after considering inclusion and exclusion criteria for qualitative evidence synthesis.

• They enrolled four retrospective studies to evaluate the SARS-CoV-2 infection risk in PCa patients under ADT vs. no ADT and the summarized risk ratio (RR) was 0.8 (95% confidence intervals (CI) 0.44–1.47).

• They included five retrospective studies to evaluate the severity of coronavirus disease 2019 (COVID-19) in PCa patients under ADT vs no ADT and the summarized RR was 1.23 (95% CI 0.9–1.68).